Prevalence of drug-resistant tuberculosis in Iran: Systematic review and meta-analysis

• Published in: American journal of infection control Vol. 42; no. 11; pp. 1212 - 1218
• Main Authors: Nasiri, Mohammad Javad, PhD, Dabiri, Hossein, PhD, Darban-Sarokhalil, Davood, PhD, Rezadehbashi, Maryam, PhD, Zamani, Samin, PhD
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.11.2014; Elsevier; Mosby-Year Book, Inc
• Subjects: Antitubercular Agents - pharmacology; Bacterial diseases; Biological and medical sciences; Drug resistance; Epidemiology. Vaccinations; General aspects; Human bacterial diseases; Humans; Infection Control; Infectious Disease; Infectious diseases; Iran; Iran - epidemiology; Isoniazid - pharmacology; Medical sciences; Meta-analysis; Multidrug resistant organisms; Prevalence; Public health; Streptomycin - pharmacology; Systematic review; Tuberculosis; Tuberculosis and atypical mycobacterial infections; Tuberculosis, Multidrug-Resistant - epidemiology; Iran; Asia; Iran; Drug resistance; Tuberculosis; Infection; Prevention; Treatment resistance; Prevalence; Bacteriosis; Check; Mycobacterial infection; Epidemiology; Bibliographic review
• ISSN: 0196-6553; 1527-3296
• DOI: 10.1016/j.ajic.2014.07.017

Background The spread of multidrug-resistant tuberculosis (MDR-TB) is a major public health problem worldwide. Although drug resistance is common in some countries and rare in others, the extent of this condition is not precisely known in Iran. Methods We searched several databases including PubMed, Web of Science, Scopus, Iran Medex, and Scientific Information Database to identify studies addressing drug-resistant tuberculosis in Iran. A total of 19 reports published from different regions of Iran from March 1999-May 2013 were included in this study. Results The meta-analyses revealed that 23% (95% confidence interval [CI], 21.8-24.2) of new cases and 65.6% (95% CI, 62.5-68.5) of previously treated cases were resistant to at least 1 drug. Furthermore, MDR-TB was found in 5.1% (95% CI, 4.4-5.8) of new cases, whereas it was found in 33.7% (95% CI, 30.8-36.7) of retreatment cases. The highest rate of resistance in new and previously treated cases was seen against streptomycin (19%) and isoniazid (47%), respectively. Conclusion The results of the present study underscore the need for further enforcement of TB control strategies. Drug susceptibility testing, establishing advanced diagnostic facilities, and continuous monitoring of drug resistance are recommended for prevention and control of MDR-TB.